Working… Menu

Monitoring Noninvasively for Infusion and Transfusion Optimization

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04388722
Recruitment Status : Withdrawn (Sponsor's decision to withdraw study.)
First Posted : May 14, 2020
Last Update Posted : December 14, 2020
Information provided by (Responsible Party):
Masimo Corporation

Brief Summary:
This is a multicenter, cluster randomized controlled trial to assess the effects of an optimized intraoperative fluid and blood management strategy on postoperative complications.

Condition or disease Intervention/treatment Phase
Post Operative Hemorrhage Transfusion Related Complication Blood Transfusion Associated Adverse Reactions Hypovolemia Device: Pulse CO-Oximeter Sensor Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Other
Official Title: Monitoring Noninvasively for Infusion and Transfusion Optimization in a Randomized (MONITOR) Trial
Estimated Study Start Date : December 10, 2020
Estimated Primary Completion Date : December 10, 2020
Estimated Study Completion Date : December 10, 2020

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
No Intervention: Control Arm
Experimental: Investigational Arm Device: Pulse CO-Oximeter Sensor
Investigational Pulse CO-Oximeter sensor will measure hemoglobin (SpHb) and pleth variability index (PVi).

Primary Outcome Measures :
  1. Post-operative complication [ Time Frame: 7 days ]
    Occurrence of at least one post-operative complication by day 7 after surgery.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 18 years or older at the time of consent.
  • Ability to provide written informed consent.
  • Scheduled for non-urgent major surgery with general anesthesia
  • At least one finger available and accessible for performing non-invasive pleth variability index (PVi) and hemoglobin (SpHb) monitoring.
  • The Attending surgeon, attending anesthesiologist and the clinical care team agree with enrollment in the study, including the restrictions on monitoring procedures defined in the control group.

Exclusion Criteria:

  • Untreated or uncontrolled hypertension defined as mean arterial pressure (MAP) greater than 120 mmHg, despite medications.
  • Chronic kidney disease with glomerular filtration rate <30 ml/min/1.73 m2 or requiring renal-replacement therapy for end-stage renal disease.
  • Surgeries where no bleeding is expected to occur (i.e., total knee surgery where blood loss is prevented by use of tourniquet).
  • Surgeries performed in the prone position.
  • Acute cardiovascular event, including acute or decompensated heart failure and acute coronary syndrome.
  • Aortic pathology that could lead to misinterpretation of hemodynamic variables (e.g. intra- aortic balloon pump, thoracic aorta aneurysm).
  • Renal vascular surgery.
  • Preoperative sepsis.
  • Circulatory shock.
  • Preoperative vasoactive substance infusion before study entry.
  • Concurrent participation in any interventional study.
  • Pregnant or lactating women.
  • Patients who refuse to receive blood transfusion(s).
  • Patients with Do Not Resuscitate (DNR) orders.
  • Open chest surgeries.
  • Prisoners
  • Patients for whom monitoring of CO, SV, PPV, and/or SVV to guide GDT or similar intra-operative fluid management, including continuous SpHb monitoring, would be standard of care.
  • Patients have skin abnormalities affecting the digits such as psoriasis, eczema, angioma, scar tissue, burn, fungal infection, substantial skin breakdown, nail polish or acrylic nails that would prevent the proper fit and application of the sensors.
  • Cardio-pulmonary bypass (CPB) surgery.
Layout table for additonal information
Responsible Party: Masimo Corporation Identifier: NCT04388722    
Other Study ID Numbers: MONITOR
First Posted: May 14, 2020    Key Record Dates
Last Update Posted: December 14, 2020
Last Verified: December 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Transfusion Reaction
Blood Loss, Surgical
Postoperative Hemorrhage
Pathologic Processes
Intraoperative Complications
Postoperative Complications
Hematologic Diseases
Immune System Diseases